Report
ABGSC Healthcare Research ...
  • Georg Tigalonov-Bjerke

Learn from the first, deliver on the second

Underlying
Isofol Medical AB

Isofol Medical AB (publ) is a Sweden-based clinical stage pharmaceutical company. Its primary product is Modufolin, the active metabolite. Modufolin is a folate-based compound, which increases the efficiency and reduces the side effects of chemotherapy. Modufolin contains the key active substance methylenetetrahydrofolate (MTHF), which is the active metabolite in all folate-based medicines and therefore does not require metabolic activation to exert its action. The Company cooperates with pharmaceutical manufacturer Merck & Co Inc, as well as the Company has a worldwide supply and licence agreement for the use of Modufolin in cancer treatment. The Company's main shareholders are Biofol AB and Yield Life Science AB.

Provider
ABG Sundal Collier Sponsored
ABG Sundal Collier Sponsored

ABG Sundal Collier is the independent, Nordic investment banking powerhouse, developed over 30 years, founded on a hard working partnership culture and the ability to attract top talent.

Our strategy is to be an advisor and an intermediary, and the core product offering comprise corporate advisory services, corporate financing services and investor research and brokerage services.

Our corporate advisory team offers access to a broad financial and industrial network and unparalleled transaction experience. We provide financing to corporates through our superior Nordic and international distribution platform, and we are optimally structured for naturally matching trading flows, delivering best execution for clients.

The group employ approx. 250 staff working from the Nordic offices in Norway, Sweden and Denmark and in the offices in the key international markets US, UK and Germany. 


Analysts
ABGSC Healthcare Research

Georg Tigalonov-Bjerke

ResearchPool Subscriptions

Get the most out of your insights

Get in touch